News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Three Adimab LLC. Antibodies Enter Human Clinical Trials



1/12/2012 6:12:48 AM

LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a leader in the discovery of fully human antibodies, today announced that its partner, Merrimack Pharmaceuticals, Inc. of Cambridge, MA, has initiated the first human clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). The three lead antibodies and a number of backups were discovered by Adimab and licensed exclusively to Merrimack.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES